Reminder of Lufax Securities Class Action
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 06 2026
0mins
Should l Buy LU?
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Lufax securities between April 7, 2023, and January 26, 2025, that they must apply to be lead plaintiff by May 20, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Lufax made false and misleading statements during the class period, failing to disclose inadequate internal controls and materially misstated financial results, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its success and expertise in this field.
- Participation Instructions: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, ensuring they select qualified legal counsel to protect their rights in the lawsuit and avoid inexperienced intermediaries.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LU?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LU
About LU
LUFAX HOLDING LTD is a holding company mainly engaged in providing financial services for small and micro enterprises. The Company's core retail credit enablement business includes bank-funded loans, trust-funded loans and consumer finance loans. The Company is also engaged in wealth management and providing access to financial products and services. The Company conducts the business through its subsidiaries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of Lufax Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Lufax securities between April 7, 2023, and January 26, 2025, to apply as lead plaintiffs by May 20, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Lufax failed to disclose inadequate internal controls and materially misstated financial results during the class period, resulting in investor losses when the true information was revealed, thereby damaging the company's reputation and shareholder confidence.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its expertise and success in this field.
- Investor Action Advice: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, ensuring they select qualified legal counsel to effectively represent them in the lawsuit and avoid inexperienced intermediary firms.
See More
Lufax Faces Class Action Lawsuit for Investor Rights
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Lufax in the Central District of California, representing investors who purchased Lufax securities between April 7, 2023, and January 26, 2025, indicating strong investor dissatisfaction with the company's financial transparency.
- Allegation Details Revealed: The lawsuit alleges that Lufax failed to disclose inadequate internal controls and materially misstated financial results during the class period, leading to investor losses when the true information was revealed, highlighting significant flaws in the company's governance structure.
- Investor Rights Protection: Investors must apply by May 20, 2026, to be appointed as lead plaintiffs, reflecting concerns over corporate governance and financial reporting that could impact Lufax's market reputation and stock price.
- Legal Consultation Channels: Bragar Eagel & Squire offers free consultations, encouraging affected investors to contact attorneys directly, demonstrating the law firm's commitment to protecting investor rights.
See More
Lufax Faces Class Action Lawsuit, Shares Plunge 14%
- Class Action Initiated: A class action lawsuit has been filed against Lufax for securities transactions between April 7, 2023, and January 26, 2025, representing investors seeking to recover losses, highlighting serious concerns over the company's financial transparency.
- Auditor Dismissal: On January 27, 2025, Lufax announced the dismissal of PricewaterhouseCoopers as its auditor due to concerns over undisclosed related-party transactions, triggering a nearly 14% drop in share price that day, reflecting a crisis of trust in corporate governance.
- Financial Reporting Allegations: The lawsuit alleges that Lufax lacked adequate internal controls and that its financial results were materially misstated, severely undermining investor confidence in the company's financial health and potentially impacting its future financing capabilities.
- Investigation and Whistleblower Mechanism: Hagens Berman is investigating whether Lufax intentionally violated accounting rules and encourages whistleblowers to come forward, indicating strong scrutiny on the company's transparency and compliance, which could lead to broader legal repercussions.
See More
Class Action Lawsuits Filed for Multiple Companies
- Lufax Shareholder Lawsuit: Shareholders of Lufax Holding Ltd. have filed a class action due to the company's failure to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, with a lead plaintiff deadline of May 20, 2026.
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics, Inc. shareholders initiated a lawsuit for the period from May 20, 2024, to January 9, 2026, alleging undisclosed manufacturing issues and clinical trial risks that jeopardized FDA approval prospects, with a lead plaintiff deadline of May 22, 2026.
- Coty Shareholder Class Action: Coty Inc. shareholders have filed a class action due to the company's failure to disclose underperformance in its Consumer Beauty segment and slowing market growth from November 5, 2025, to February 4, 2026, with a lead plaintiff deadline of May 22, 2026.
- Legal Consultation Information: The Law Offices of Frank R. Cruz remind investors who suffered losses during these periods to contact them for legal advice to protect their rights and interests.
See More
Lufax Faces Securities Class Action Lawsuit
- Lawsuit Background: Lufax announced the removal of its auditor on January 27, 2025, due to concerns over undisclosed related-party transactions, triggering a nearly 14% drop in share price that day, highlighting severe investor skepticism regarding the company's financial transparency.
- Internal Control Deficiencies: The class action alleges that Lufax lacked adequate internal controls and that certain financial results were materially misstated, with investors beginning to realize this truth on January 27, 2025, potentially undermining broader investor confidence.
- Auditor Opinion Rejection: PwC refused to consent to the incorporation of its audit opinions for 2022 and 2023 in any future company filings, indicating serious questions about the company's compliance with financial reporting standards, which could lead to wider legal and financial repercussions.
- Ongoing Investigation: Hagens Berman is investigating whether Lufax intentionally violated accounting rules and disclosure requirements, and if confirmed, this could expose the company to greater legal liabilities and financial losses.
See More
Lufax Faces Class Action Lawsuit for Securities Fraud
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Lufax and certain officers, aiming to recover damages for investors who purchased Lufax securities between April 7, 2023, and January 26, 2025, highlighting serious concerns over the company's internal controls and financial reporting.
- Allegations Detailed: The complaint alleges that Lufax failed to disclose inadequate internal controls and materially misstated financial results during the class period, misleading investors about the company's business and prospects, which could adversely affect its stock price and market reputation.
- Investor Participation: Affected investors must apply to be lead plaintiffs by May 20, 2026, indicating the urgency of the case and the protection of investor rights, which may influence future legal outcomes and compensation amounts.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman LLC is recognized for recovering hundreds of millions for investors, emphasizing its expertise in securities fraud class actions, potentially attracting more investors to join the lawsuit to safeguard their interests.
See More
Reminder of Lufax Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Lufax securities between April 7, 2023, and January 26, 2025, to apply as lead plaintiffs by May 20, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Lufax failed to disclose inadequate internal controls and materially misstated financial results during the class period, resulting in investor losses when the true information was revealed, thereby damaging the company's reputation and shareholder confidence.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its expertise and success in this field.
- Investor Action Advice: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, ensuring they select qualified legal counsel to effectively represent them in the lawsuit and avoid inexperienced intermediary firms.
See More
Lufax Faces Class Action Lawsuit for Investor Rights
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Lufax in the Central District of California, representing investors who purchased Lufax securities between April 7, 2023, and January 26, 2025, indicating strong investor dissatisfaction with the company's financial transparency.
- Allegation Details Revealed: The lawsuit alleges that Lufax failed to disclose inadequate internal controls and materially misstated financial results during the class period, leading to investor losses when the true information was revealed, highlighting significant flaws in the company's governance structure.
- Investor Rights Protection: Investors must apply by May 20, 2026, to be appointed as lead plaintiffs, reflecting concerns over corporate governance and financial reporting that could impact Lufax's market reputation and stock price.
- Legal Consultation Channels: Bragar Eagel & Squire offers free consultations, encouraging affected investors to contact attorneys directly, demonstrating the law firm's commitment to protecting investor rights.
See More
Lufax Faces Class Action Lawsuit, Shares Plunge 14%
- Class Action Initiated: A class action lawsuit has been filed against Lufax for securities transactions between April 7, 2023, and January 26, 2025, representing investors seeking to recover losses, highlighting serious concerns over the company's financial transparency.
- Auditor Dismissal: On January 27, 2025, Lufax announced the dismissal of PricewaterhouseCoopers as its auditor due to concerns over undisclosed related-party transactions, triggering a nearly 14% drop in share price that day, reflecting a crisis of trust in corporate governance.
- Financial Reporting Allegations: The lawsuit alleges that Lufax lacked adequate internal controls and that its financial results were materially misstated, severely undermining investor confidence in the company's financial health and potentially impacting its future financing capabilities.
- Investigation and Whistleblower Mechanism: Hagens Berman is investigating whether Lufax intentionally violated accounting rules and encourages whistleblowers to come forward, indicating strong scrutiny on the company's transparency and compliance, which could lead to broader legal repercussions.
See More
Class Action Lawsuits Filed for Multiple Companies
- Lufax Shareholder Lawsuit: Shareholders of Lufax Holding Ltd. have filed a class action due to the company's failure to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, with a lead plaintiff deadline of May 20, 2026.
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics, Inc. shareholders initiated a lawsuit for the period from May 20, 2024, to January 9, 2026, alleging undisclosed manufacturing issues and clinical trial risks that jeopardized FDA approval prospects, with a lead plaintiff deadline of May 22, 2026.
- Coty Shareholder Class Action: Coty Inc. shareholders have filed a class action due to the company's failure to disclose underperformance in its Consumer Beauty segment and slowing market growth from November 5, 2025, to February 4, 2026, with a lead plaintiff deadline of May 22, 2026.
- Legal Consultation Information: The Law Offices of Frank R. Cruz remind investors who suffered losses during these periods to contact them for legal advice to protect their rights and interests.
See More
Lufax Faces Securities Class Action Lawsuit
- Lawsuit Background: Lufax announced the removal of its auditor on January 27, 2025, due to concerns over undisclosed related-party transactions, triggering a nearly 14% drop in share price that day, highlighting severe investor skepticism regarding the company's financial transparency.
- Internal Control Deficiencies: The class action alleges that Lufax lacked adequate internal controls and that certain financial results were materially misstated, with investors beginning to realize this truth on January 27, 2025, potentially undermining broader investor confidence.
- Auditor Opinion Rejection: PwC refused to consent to the incorporation of its audit opinions for 2022 and 2023 in any future company filings, indicating serious questions about the company's compliance with financial reporting standards, which could lead to wider legal and financial repercussions.
- Ongoing Investigation: Hagens Berman is investigating whether Lufax intentionally violated accounting rules and disclosure requirements, and if confirmed, this could expose the company to greater legal liabilities and financial losses.
See More
Lufax Faces Class Action Lawsuit for Securities Fraud
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Lufax and certain officers, aiming to recover damages for investors who purchased Lufax securities between April 7, 2023, and January 26, 2025, highlighting serious concerns over the company's internal controls and financial reporting.
- Allegations Detailed: The complaint alleges that Lufax failed to disclose inadequate internal controls and materially misstated financial results during the class period, misleading investors about the company's business and prospects, which could adversely affect its stock price and market reputation.
- Investor Participation: Affected investors must apply to be lead plaintiffs by May 20, 2026, indicating the urgency of the case and the protection of investor rights, which may influence future legal outcomes and compensation amounts.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman LLC is recognized for recovering hundreds of millions for investors, emphasizing its expertise in securities fraud class actions, potentially attracting more investors to join the lawsuit to safeguard their interests.
See More
